Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of single-ascending dose of MMI-0100 in volunteers in the Netherlands

Trial Profile

Phase I trial of single-ascending dose of MMI-0100 in volunteers in the Netherlands

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MMI 0100 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Moerae Matrix
  • Most Recent Events

    • 23 May 2018 Results assessing the safety, tolerability and PK profile of IH MMI-0100 in three Phase I trials (n=75) presented at the 114th International Conference of the American Thoracic Society
    • 28 Jul 2015 Results published in a Moerae Matrix media release.
    • 28 Jul 2015 Status changed from recruiting to completed according to a Moerae Matrix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top